Respiratory Symptoms in Palliative Care

Dyspnoea can arise from physiological, psychological, social and environmental factors together. Patients are frightened by the sensation — they feel they are suffocating. Severe respiratory distress is a medical emergency and should be treated as such even in a patient who is dying.

Non-pharmacological management

• Avoid covering the face, or directing shower water/airflow into the face.
• Air movement directed at the cheek may reduce breathlessness — supported by randomised controlled trial evidence; a simple handheld fan is a reasonable, low-risk first step.
• Walking aids (wheeled walkers/rollators rather than single-point sticks) increase exercise tolerance by stabilising the ribcage.
• Energy conservation — pacing activity and using mobility aids demonstrably improves quality of life and reduces hospitalisation.
• Breathing exercises (e.g. pursed-lip breathing) increase exercise tolerance, though their effect on the sensation of breathlessness itself is less certain.
• Psychological strategies (e.g. CBT) can reduce breathlessness, anxiety and depression together.
• Educate the patient on the cause of their dyspnoea.

Pharmacological management

Oxygen — give if the patient is hypoxic. For non-hypoxic patients, there is no advantage over room air; use only after discussing the patient’s own preference, since some find it psychologically reassuring regardless.

Opioids and benzodiazepines — the distress of dyspnoea often perpetuates itself, so an opioid or benzodiazepine can help those with significant anxiety/distress. A recent RCT found sustained-release morphine ineffective specifically for COPD-related breathlessness, shifting practice toward reserving opioids for patients with limited other options rather than routine first-line use — though the titrated immediate-release regimen below remains appropriate once that decision is made, and is generally safe even in type 2 respiratory failure with mild, self-limiting side effects.

For the opioid-naive patient:

Drug	Regimen
Morphine (oral)	1–2.5 mg immediate-release, repeated 1-hourly as required
Morphine (SC)	0.5–1 mg, repeated 1-hourly as required

If dyspnoea continues:

Drug	Regimen
Morphine (oral)	1–2.5 mg 4-hourly regularly, plus 1–2.5 mg 1-hourly PRN
Morphine (SC)	0.5–1 mg 4-hourly regularly, plus 0.5–1 mg 1-hourly PRN
Morphine modified-release (oral)	5–10 mg twice daily, plus 1–2.5 mg immediate-release 1-hourly PRN

If the patient is already on regular opioids, use a benzodiazepine instead:

Drug	Regimen
Oxazepam	7.5–15 mg oral, repeated after 1 hour PRN
Lorazepam	0.5–1 mg oral/sublingual, repeated after 1 hour PRN
Midazolam	2.5 mg SC, repeated after 1 hour PRN

Note: lorazepam’s evidence base is specifically for breathlessness-associated anxiety, not for breathlessness itself directly — there’s no evidence benzodiazepines relieve the sensation of dyspnoea independent of anxiety.

If via syringe driver: midazolam 5–10 mg/24 hours by continuous SC infusion.

Systemic corticosteroids — evidence is limited, but a trial of dexamethasone 4–8 mg daily can be considered for a suspected inflammatory cause (e.g. lymphangitis, radiation pneumonitis); cease after 3–5 days if no benefit.

Assessing the underlying cause

Look for PE, pneumonia, SVC obstruction, pleural/pericardial effusion, airway obstruction. If a reversible cause exists within the patient’s palliative scope, treat it (e.g. antibiotics, diuretics).

Cough and haemoptysis

Severe cough can be managed with opioids and benzodiazepines as for generally distressed patients.

• Mild haemoptysis: tranexamic acid 0.5–1.5 g orally, 2–3 times daily.
• Large haemoptysis: consider interventions to stop bleeding depending on cause, but severe bleeding often has a poor outcome. If anticipated, counsel the patient and family in advance on managing it conservatively with sedation.

From eTG and AJGP August 2025 (Palliative management of breathlessness).